Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition

Experimental Hematology

Volumn 44, Issue 5, 2016, Pages 315-321

  Kuo, Ya Huei ^a   Qi, Jing ^a   Cook, Guerry J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD135 ANTIGEN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 8 ISOFORM SELECTIVE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; ISOENZYME; MYC PROTEIN; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; SIRTUIN 1; TENOVIN 6; UNCLASSIFIED DRUG; HDAC8 PROTEIN, HUMAN; REPRESSOR PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CHROMOSOME 16; CHROMOSOME INVERSION; CHRONIC MYELOID LEUKEMIA; DEACETYLATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SPECIFICITY; GENE DUPLICATION; GENE INACTIVATION; GENE MUTATION; HUMAN; INTERNAL TANDEM DUPLICATION; LEUKEMIA STEM CELL; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR SUPPRESSOR GENE; ACETYLATION; ACUTE DISEASE; BIOLOGICAL MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; MYELOID LEUKEMIA;

ACETYLATION; ACUTE DISEASE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, MYELOID; MODELS, BIOLOGICAL; MUTATION; NEOPLASTIC STEM CELLS; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84963610750     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2016.02.007     Document Type: Review

References (133)

1. Dick J.E. Acute myeloid leukemia stem cells. Ann NY Acad Sci 2005, 1044:1-5.
2. Chan W.I., Huntly B.J.P. Leukemia stem cells in acute myeloid leukemia. Semin Oncol 2008, 35:326-335.
3. Reinisch A., Chan S.M., Thomas D., Majeti R. Biology and clinical relevance of acute myeloid leukemia stem cells. Semin Hematol 2015, 52:150-164.
4. Corces-Zimmerman M.R., Majeti R. Pre-leukemic evolution of hematopoietic stem cells: The importance of early mutations in leukemogenesis. Leukemia 2014, 28:2276-2282.
5. Shlush L.I., Zandi S., Mitchell A., et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014, 506:328-333.
6. Corces-Zimmerman M.R., Hong W.J., Weissman I.L., Medeiros B.C., Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A 2014, 111:2548-2553.
7. Vousden K.H., Lane D.P. p53 in health and disease. Nat Rev Mol Cell Biol 2007, 8:275-283.
8. Kruiswijk F., Labuschagne C.F., Vousden K.H. p53 in survival, death and metabolic health: A lifeguard with a license to kill. Nat Rev Mol Cell Biol 2015, 16:393-405.
9. Green D.R., Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009, 458:1127-1130.
10. Rücker F.G., Schlenk R.F., Bullinger L., et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012, 119:2114-2121.
11. Wong T.N., Ramsingh G., Young A.L., et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 2015, 518:552-555.
12. Haferlach C., Dicker F., Herholz H., Schnittger S., Kern W., Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 2008, 22:1539-1541.
13. Ok C.Y., Patel K.P., Garcia-Manero G., et al. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol 2015, 8:45.
14. Wattel E., Preudhomme C., Hecquet B., et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994, 84:3148-3157.
15. Nakano Y., Naoe T., Kiyoi H., et al. Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia. Eur J Haematol 2000, 65:23-31.
16. Brooks C.L., Gu W. P53 regulation by ubiquitin. FEBS Lett 2011, 585:2803-2809.
17. Marouco D., Garabadgiu A.V., Melino G., Barlev N.A. Lysine-specific modifications of p53: A matter of life and death?. Oncotarget 2013, 4:1556-1571.
18. Brooks C.L., Gu W. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell 2011, 2:456-462.
19. Dai C., Gu W. p53 post-translational modification: Deregulated in tumorigenesis. Trends Mol Med 2010, 16:528-536.
20. Bueso-Ramos C.E., Yang Y., deLeon E., McCown P., Stass S.A., Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993, 82:2617-2623.
21. Bueso-Ramos C.E., Manshouri T., Haidar M.A., Huh Y.O., Keating M.J., Albitar M. Multiple patterns of MDM-2 deregulation in human leukemias: Implications in leukemogenesis and prognosis. Leuk Lymphoma 1995, 17:13-18.
22. Seliger B., Papadileris S., Vogel D., et al. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. Eur J Haematol 1996, 57:230-240.
23. Vassilev L.T., Vu B.T., Graves B., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
24. Ding K., Lu Y., Nikolovska-Coleska Z., et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the mdm2-p53 interaction. J Med Chem 2006, 49:3432-3435.
25. Secchiero P., Zerbinati C., Melloni E., et al. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts. Neoplasia 2007, 9:853-861.
26. Shangary S., Qin D., McEachern D., et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A 2008, 105:3933-3938.
27. Kurosu T., Wu N., Oshikawa G., Kagechika H., Miura O. Enhancement of imatinib-induced apoptosis of BCR/abl-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway. Apoptosis 2010, 15:608-620.
28. Ding Q., Zhang Z., Liu J.J., et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem 2013, 56:5979-5983.
29. Zhang Z., Ding Q., Liu J.J., et al. Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy. Bioorg Med Chem 2014, 22:4001-4009.
30. Andreeff M., Kelly K.R., Yee K., et al. Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia. Clin Cancer Res 2016, 22:868-876.
31. Carter B.Z., Mak P.Y., Mak D.H., et al. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of bcl-2 or bcr-abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget 2015, 6:30487-30499.
32. Long J., Parkin B., Ouillette P., et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood 2010, 116:71-80.
33. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
34. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008, 269:7-17.
35. Frew A.J., Johnstone R.W., Bolden J.E. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009, 280:125-133.
36. Ma X., Ezzeldin H.H., Diasio R.B. Histone deacetylase inhibitors: Current status and overview of recent clinical trials. Drugs 2009, 69:1911-1934.
37. Wanczyk M., Roszczenko K., Marcinkiewicz K., Bojarczuk K., Kowara M., Winiarska M. HDACi-Going through the mechanisms. Front Biosci 2011, 16:340-359.
38. Khan N., Jeffers M., Kumar S., et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008, 409:581-589.
39. Juan L.J., Shia W.J., Chen M.H., et al. Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 2000, 275:20436-20443.
40. Luo J., Su F., Chen D., Shiloh A., Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000, 408:377-381.
41. Ito A., Kawaguchi Y., Lai C.H., et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002, 21:6236-6245.
42. Luo J., Nikolaev A.Y., Imai S., et al. Negative control of p53 by sir2alpha promotes cell survival under stress. Cell 2001, 107:137-148.
43. Vaziri H., Dessain S.K., Ng Eaton E., et al. HSIR2(SIRT1) functions as an nad-dependent p53 deacetylase. Cell 2001, 107:149-159.
44. Prives C., Manley J.L. Why is p53 acetylated?. Cell 2001, 107:815-818.
45. Tang Y., Zhao W., Chen Y., Zhao Y., Gu W. Acetylation is indispensable for p53 activation. Cell 2008, 133:612-626.
46. Melo J.V., Barnes D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007, 7:441-453.
47. Sawyers C.L. Chronic myeloid leukemia. N Engl J Med 1999, 340:1330-1340.
48. Eiring A.M., Khorashad J.S., Morley K., Deininger M.W. Advances in the treatment of chronic myeloid leukemia. BMC Med 2011, 9:99.
49. Holtz M.S., Forman S.J., Bhatia R. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 2005, 19:1034-1041.
50. Chu S., McDonald T., Lin A., et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 2011, 118:5565-5572.
51. Barnes D.J., Melo J.V. Primitive, quiescent and difficult to kill: The role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 2006, 5:2862-2866.
52. Corbin A.S., Agarwal A., Loriaux M., Cortes J., Deininger M.W., Druker B.J. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011, 121:396-409.
53. Shah N.P., Nicoll J.M., Nagar B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
54. Branford S., Rudzki Z., Walsh S., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (p-loop) are associated with a poor prognosis. Blood 2003, 102:276-283.
55. Hughes T.P., Saglio G., Quintás-Cardama A., et al. BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia 2015, 29:1832-1838.
56. Bordone L., Guarente L. Calorie restriction, SIRT1 and metabolism: Understanding longevity. Nat Rev Mol Cell Biol 2005, 6:298-305.
57. Liu T., Liu P.Y., Marshall G.M. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 2009, 69:1702-1705.
58. Singh S.K., Williams C.A., Klarmann K., Burkett S.S., Keller J.R., Oberdoerffer P. Sirt1 ablation promotes stress-induced loss of epigenetic and genomic hematopoietic stem and progenitor cell maintenance. J Exp Med 2013, 210:987-1001.
59. Ou X., Chae H.-D., Wang R.H., et al. SIRT1 deficiency compromises mouse embryonic stem cell hematopoietic differentiation, and embryonic and adult hematopoiesis in the mouse. Blood 2011, 117:440-450.
60. Wang Z., Yuan H., Roth M., Stark J.M., Bhatia R., Chen W.Y. SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. Oncogene 2013, 32:589-598.
61. Yi J., Luo J. SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta 2010, 1804:1684-1689.
62. Brooks C.L., Gu W. How does SIRT1 affect metabolism, senescence and cancer?. Nat Rev Cancer 2009, 9:123-128.
63. Chen W.Y., Wang D.H., Yen R.C., Luo J., Gu W., Baylin S.B. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent dna-damage responses. Cell 2005, 123:437-448.
64. Strum J.C., Johnson J.H., Ward J., et al. MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of sirt1. Mol Endocrinol 2009, 23:1876-1884.
65. Yuan H., Wang Z., Li L., et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 2012, 119:1904-1914.
66. Li L., Wang L., Li L., et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012, 21:266-281.
67. Lain S., Hollick J.J., Campbell J., et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008, 13:454-463.
68. Wang Z., Chen C.C., Chen W. CD150(-) side population defines leukemia stem cells in a BALB/c mouse model of CML and is depleted by genetic loss of SIRT1. Stem Cells 2015, 33:3437-3451.
69. Döhner H., Weisdorf D.J., Bloomfield C.D. Acute myeloid leukemia. N Engl J Med 2015, 373:1136-1152.
70. Marcucci G., Mrózek K., Bloomfield C.D. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 2005, 12:68-75.
71. Gaidzik V., Döhner K. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 2008, 35:346-355.
72. Scholl S., Fricke H.J., Sayer H.G., Höffken K. Clinical implications of molecular genetic aberrations in acute myeloid leukemia. J Cancer Res Clin Oncol 2009, 135:491-505.
73. Marcucci G., Haferlach T., Döhner H. Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic implications. J Clin Oncol 2011, 29:475-486.
74. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
75. Sanders M.A., Valk P.J. The evolving molecular genetic landscape in acute myeloid leukaemia. Curr Opin Hematol 2013, 20:79-85.
76. Cancer Genome Atlas Research Network Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013, 368:2059-2074.
77. Bodini M., Ronchini C., Giacò L., et al. The hidden genomic landscape of acute myeloid leukemia: Subclonal structure revealed by undetected mutations. Blood 2015, 125:600-605.
78. Nakao M., Yokota S., Iwai T., et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10:1911-1918.
79. Sallmyr A., Fan J., Datta K., et al. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: Implications for poor prognosis in AML. Blood 2008, 111:3173-3182.
80. Kindler T., Lipka D.B., Fischer T. FLT3 as a therapeutic target in AML: Still challenging after all these years. Blood 2010, 116:5089-5102.
81. Thiede C., Steudel C., Mohr B., et al. Analysis of flt3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
82. Fröhling S., Schlenk R.F., Breitruck J., et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML study group ulm. Blood 2002, 100:4372-4380.
83. Meshinchi S., Woods W.G., Stirewalt D.L., et al. Prevalence and prognostic significance of flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001, 97:89-94.
84. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98:1752-1759.
85. Kiyoi H., Towatari M., Yokota S., et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998, 12:1333-1337.
86. Mizuki M., Fenski R., Halfter H., et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the ras and STAT5 pathways. Blood 2000, 96:3907-3914.
87. Fenski R., Flesch K., Serve S., et al. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol 2000, 108:322-330.
88. Kiyoi H., Ohno R., Ueda R., Saito H., Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 2002, 21:2555-2563.
89. Tse K.F., Novelli E., Civin C.I., Bohmer F.D., Small D. Inhibition of flt3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 2001, 15:1001-1010.
90. Hayakawa F., Towatari M., Kiyoi H., et al. Tandem-duplicated flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in il-3-dependent cell lines. Oncogene 2000, 19:624-631.
91. Yoshimoto G., Miyamoto T., Jabbarzadeh-Tabrizi S., et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via flt3-itd-specific STAT5 activation. Blood 2009, 114:5034-5043.
92. Chu S.H., Heiser D., Li L., et al. FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm. Cell Stem Cell 2012, 11:346-358.
93. Grundler R., Thiede C., Miething C., Steudel C., Peschel C., Duyster J. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood 2003, 102:646-651.
94. Knapper S., Burnett A.K., Littlewood T., et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006, 108:3262-3270.
95. Weisberg E., Boulton C., Kelly L.M., et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002, 1:433-443.
96. Levis M., Ravandi F., Wang E.S., et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011, 117:3294-3301.
97. Levis M. Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia. Future Oncol 2014, 10:1571-1579.
98. Swords R., Freeman C., Giles F. Targeting the fms-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia 2012, 26:2176-2185.
99. Smith C.C., Wang Q., Chin C.S., et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012, 485:260-263.
100. Li L., Osdal T., Ho Y., et al. SIRT1 activation by a c-myc oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell 2014, 15:431-446.
101. Lin Z., Yang H., Kong Q., et al. USP22 antagonizes p53 transcriptional activation by deubiquitinating sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol Cell 2012, 46:484-494.
102. Choudhary C., Olsen J.V., Brandts C., et al. Mislocalized activation of oncogenic rtks switches downstream signaling outcomes. Mol Cell 2009, 36:326-339.
103. Kim K.T., Baird K., Ahn J.Y., et al. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in flt3-mediated cell survival. Blood 2005, 105:1759-1767.
104. Sasca D., Hähnel P.S., Szybinski J., et al. SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood 2014, 124:121-133.
105. Look A.T. Oncogenic transcription factors in the human acute leukemias. Science 1997, 278:1059-1064.
106. Speck N.A., Stacy T., Wang Q., et al. Core-binding factor: A central player in hematopoiesis and leukemia. Cancer Res 1999, 59(7 Suppl):1789s-1793s.
107. Speck N.A., Gilliland D.G. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2002, 2:502-513.
108. Liu P.P., Wijmenga C., Hajra A., et al. Identification of the chimeric protein product of the CBFB-MYH11 fusion gene in inv(16) leukemia cells. Genes Chromosomes Cancer 1996, 16:77-87.
109. Liu P., Tarlé S.A., Hajra A., et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 1993, 261:1041-1044.
110. Liu P.P., Hajra A., Wijmenga C., Collins F.S. Molecular pathogenesis of the chromosome 16 inversion in the m4eo subtype of acute myeloid leukemia. Blood 1995, 85:2289-2302.
111. Castilla L.H., Wijmenga C., Wang Q., et al. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell 1996, 87:687-696.
112. Castilla L.H., Garrett L., Adya N., et al. The fusion gene cbfb-myh11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nat Genet 1999, 23:144-146.
113. Kuo Y.H., Landrette S.F., Heilman S.A., et al. Cbf beta-smmhc induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia. Cancer Cell 2006, 9:57-68.
114. Kuo Y.H., Gerstein R.M., Castilla L.H. Cbfbeta-SMMHC impairs differentiation of common lymphoid progenitors and reveals an essential role for RUNX in early b-cell development. Blood 2008, 111:1543-1551.
115. Zhao L., Cannons J.L., Anderson S., et al. CBFB-MYH11 hinders early T-cell development and induces massive cell death in the thymus. Blood 2007, 109:3432-3440.
116. Kanno Y., Kanno T., Sakakura C., Bae S.C., Ito Y. Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (cbfalpha) subunit by the leukemia-related PEBP2/cbfbeta-smmhc fusion protein inhibits PEBP2/cbf-mediated transactivation. Mol Cell Biol 1998, 18:4252-4261.
117. Adya N., Stacy T., Speck N.A., Liu P.P. The leukemic protein core binding factor beta (cbfbeta)-smooth-muscle myosin heavy chain sequesters cbfalpha2 into cytoskeletal filaments and aggregates. Mol Cell Biol 1998, 18:7432-7443.
118. Lutterbach B., Hou Y., Durst K.L., Hiebert S.W. The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor. Proc Natl Acad Sci U S A 1999, 96:12822-12827.
119. Durst K.L., Lutterbach B., Kummalue T., Friedman A.D., Hiebert S.W. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Mol Cell Biol 2003, 23:607-619.
120. Kuo Y.H., Zaidi S.K., Gornostaeva S., Komori T., Stein G.S., Castilla L.H. Runx2 induces acute myeloid leukemia in cooperation with cbfbeta-smmhc in mice. Blood 2009, 113:3323-3332.
121. Kamikubo Y., Zhao L., Wunderlich M., et al. Accelerated leukemogenesis by truncated CBF beta-smmhc defective in high-affinity binding with RUNX1. Cancer Cell 2010, 17:455-468.
122. Goyama S., Schibler J., Cunningham L., et al. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J Clin Invest 2013, 123:3876-3888.
123. Ben-Ami O., Friedman D., Leshkowitz D., et al. Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1. Cell Rep 2013, 4:1131-1143.
124. Hyde R.K., Zhao L., Alemu L., Liu P.P. Runx1 is required for hematopoietic defects and leukemogenesis in cbfb-myh11 knock-in mice. Leukemia 2015, 29:1771-1778.
125. Britos-Bray M., Ramirez M., Cao W., et al. CBFbeta-SMMHC, expressed in m4eo acute myeloid leukemia, reduces p53 induction and slows apoptosis in hematopoietic cells exposed to dna-damaging agents. Blood 1998, 92:4344-4352.
126. Qi J., Singh S., Hua W.K., et al. HDAC8 inhibition specifically targets inv(16) acute myeloid leukemic stem cells by restoring p53 acetylation. Cell Stem Cell 2015, 17:597-610.
127. Buggy J.J., Sideris M.L., Mak P., Lorimer D.D., McIntosh B., Clark J.M. Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochem J 2000, 350(Pt 1):199-205.
128. Van den Wyngaert I., de Vries W., Kremer A., et al. Cloning and characterization of human histone deacetylase 8. FEBS Lett 2000, 478:77-83.
129. Hu E., Chen Z., Fredrickson T., et al. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem 2000, 275:15254-15264.
130. Balasubramanian S., Ramos J., Luo W., Sirisawad M., Verner E., Buggy J.J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in t-cell lymphomas. Leukemia 2008, 22:1026-1034.
131. Huang W.J., Wang Y.C., Chao S.W., et al. Synthesis and biological evaluation of ortho-aryl n-hydroxycinnamides as potent histone deacetylase (HDAC) 8 isoform-selective inhibitors. ChemMedChem 2012, 7:1815-1824.
132. Prébet T., Boissel N., Reutenauer S., et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: A collaborative study of the French CBF-AML Intergroup. J Clin Oncol 2009, 27:4747-4753.
133. Ustun C., Marcucci G. Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia. Curr Opin Hematol 2015, 22:85-91.